Patients with STAT1 Gain-of-function Mutations Display Increased Apoptosis which is Reversed by the JAK Inhibitor Ruxolitinib
Journal of Clinical Immunology · 2024-05 · 44 (4)
DOI: 10.1007/s10875-024-01684-y ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Immunology, online erschienen am 05.04.2024. Verfasst von Laura Dotta und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Experimental Sciences, Department of Pediatrics, University of Brescia, ASST Spedali Civili of Brescia, Brescia, Italy. la…. Hauptthemen laut MEDLINE: Janus Kinase Inhibitors, Candidiasis, Chronic Mucocutaneous, Lymphopenia, Thrombocytopenia. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università degli Studi di Brescia.
Abstract (Originalsprache)
Introduction
The signal transducer and activator of transcription (STAT1) gain-of-function (GOF) syndrome accounts for most cases of chronic mucocutaneous candidiasis but is characterized by a broader clinical phenotype that may include bacterial, viral, or invasive fungal infections, autoimmunity, autoinflammatory manifestations, vascular complications, or malignancies. The severity of lymphopenia may vary and influence the infectious morbidity.
Methods
In our cohort of seven STAT1-GOF patients, we investigated the mechanisms that may determine T lymphopenia, we characterized the interferon gene signature (IGS) and analyzed the effect of ruxolitinib in reverting the immune dysregulation.
Results
STAT1-GOF patients exhibited increased T lymphocyte apoptosis that was significantly augmented in both resting conditions and following stimulation with mitogens and IFNα, as evaluated by flow cytometry by Annexin V/ Propidium iodide assay. The JAK inhibitor ruxolitinib significantly reduced the IFNα-induced hyperphosphorylation of STAT1 and reverted the stimulation-induced T-cell apoptosis, in vitro. In two adult STAT1-GOF patients, the JAKinib treatment ameliorated chronic mucocutaneous candidiasis and lymphopenia. Most STAT1-GOF patients, particularly those who had autoimmunity, presented increased IGS that significantly decreased in the two patients during ruxolitinib treatment.
Conclusion
In STAT1-GOF patients, T lymphocyte apoptosis is increased, and T lymphopenia may determine higher risk of severe infections. The JAKinib target therapy should be evaluated to treat severe chronic candidiasis and lymphopenia, and to downregulate the IFNs in patients with autoinflammatory or autoimmune manifestations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical and Experimental Sciences, Department of Pediatrics, University of Brescia, ASST Spedali Civili of Brescia, Brescia, Italy. laura.dotta@unibs.it.
- Angelo Nocivelli Institute for Molecular Medicine, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
- Department of Clinical and Experimental Sciencies, University of Brescia, Brescia, Italy.
- Department of Pediatrics, ASST Spedali Civili of Brescia and University of Brescia, Brescia, Italy.
- Department of Clinical and Experimental Sciences, Department of Pediatrics, University of Brescia, ASST Spedali Civili of Brescia, Brescia, Italy.
Förderung
- Università degli Studi di Brescia
Zitieren
APA
Dotta, L., Todaro, F., Baronio, M., Giacomelli, M., Pinelli, M., Giambarda, M., Brognoli, B., Greco, S., Rota, F., Cortesi, M., Soresina, A., Moratto, D., Tomasi, C., Ferraro, R. M., Giliani, S., & Badolato, R. (2024). Patients with STAT1 Gain-of-function Mutations Display Increased Apoptosis which is Reversed by the JAK Inhibitor Ruxolitinib. Journal of Clinical Immunology, 44(4). https://doi.org/10.1007/s10875-024-01684-y
Vancouver
Dotta L, Todaro F, Baronio M, Giacomelli M, Pinelli M, Giambarda M, et al. Patients with STAT1 Gain-of-function Mutations Display Increased Apoptosis which is Reversed by the JAK Inhibitor Ruxolitinib. Journal of Clinical Immunology. 2024;44(4). doi:10.1007/s10875-024-01684-y
BibTeX
@article{Dotta2024,
author = {Dotta, Laura and Todaro, Francesca and Baronio, Manuela and Giacomelli, Mauro and Pinelli, Marinella and Giambarda, Martina and Brognoli, Beatrice and Greco, Silvia and Rota, Francesca and Cortesi, Manuela and Soresina, Annarosa and Moratto, Daniele and Tomasi, Cesare and Ferraro, Rosalba Monica and Giliani, Silvia and Badolato, Raffaele},
title = {Patients with STAT1 Gain-of-function Mutations Display Increased Apoptosis which is Reversed by the JAK Inhibitor Ruxolitinib},
journal = {Journal of Clinical Immunology},
year = {2024},
volume = {44},
number = {4},
doi = {10.1007/s10875-024-01684-y}
}
EUVIMED